StockData
BioCardia, Inc. logo

BioCardia, Inc. (BCDA) stock

BCDANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$0.77−0.02 (-2.06%)

Close on Nov 18, 2026Market cap $11.69MP/E –Yield –

BioCardia free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

BioCardia's free cash flow for the twelve months ending Jun 30, 2026 was -$7.57M. For fiscal 2025 it was -$7.44M. The highest annual figure on record is -$310.00K in fiscal 2012.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$7.44M–
FY2024Dec 31, 2024-$7.89M–
FY2023Dec 31, 2023-$9.99M–
FY2022Dec 31, 2022-$10.63M–
FY2021Dec 31, 2021-$10.48M–
FY2020Dec 31, 2020-$12.39M–
FY2019Dec 31, 2019-$9.59M–
FY2018Dec 31, 2018-$11.14M–
FY2017Dec 31, 2017-$8.81M–
FY2015Dec 31, 2015-$7.15M–
FY2012Dec 31, 2012-$310.00K–
FY2011Dec 31, 2011-$3.22M–
FY2010Dec 31, 2010-$5.35M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$1.74M–
Q1 FY2026Mar 31, 2026-$1.66M–
Q4 FY2025Dec 31, 2025-$2.50M–
Q3 FY2025Sep 30, 2025-$1.67M–
Q2 FY2025Jun 30, 2025-$1.65M–
Q1 FY2025Mar 31, 2025-$1.62M–
Q4 FY2024Dec 31, 2024-$2.43M–
Q3 FY2024Sep 30, 2024-$2.61M–
Q2 FY2024Jun 30, 2024-$1.32M–
Q1 FY2024Mar 31, 2024-$1.53M–
Q4 FY2023Dec 31, 2023-$1.85M–
Q3 FY2023Sep 30, 2023-$2.41M–
Q2 FY2023Jun 30, 2023-$3.15M–
Q1 FY2023Mar 31, 2023-$2.57M–
Q4 FY2022Dec 31, 2022-$3.00M–
Q3 FY2022Sep 30, 2022-$2.02M–
Q2 FY2022Jun 30, 2022-$2.67M–
Q1 FY2022Mar 31, 2022-$2.94M–
Q4 FY2021Dec 31, 2021-$3.02M–
Q3 FY2021Sep 30, 2021-$2.66M–
Q2 FY2021Jun 30, 2021-$2.89M–
Q1 FY2021Mar 31, 2021-$1.91M–
Q4 FY2020Dec 31, 2020-$3.42M–
Q3 FY2020Sep 30, 2020-$3.63M–
Q2 FY2020Jun 30, 2020-$2.35M–
Q1 FY2020Mar 31, 2020-$3.00M–
Q4 FY2019Dec 31, 2019-$3.26M–
Q3 FY2019Sep 30, 2019-$1.49M–
Q2 FY2019Jun 30, 2019-$2.32M–
Q1 FY2019Mar 31, 2019-$2.52M–
Q4 FY2018Dec 31, 2018-$3.26M–
Q3 FY2018Sep 30, 2018-$2.01M–
Q2 FY2018Jun 30, 2018-$2.82M–
Q1 FY2018Mar 31, 2018-$3.04M–
Q4 FY2017Dec 31, 2017-$2.55M–
Q3 FY2017Sep 30, 2017-$1.78M–
Q2 FY2017Jun 30, 2017-$2.13M–
Q1 FY2017Mar 31, 2017-$2.34M–

More BioCardia figures

See a number that looks wrong?